Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors
Malignant Peripheral Nerve Sheath Tumors
DRUG: imatinib mesylate
Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated., Every 36 weeks
Time to progression assessed by an MRI scan., Every 36 weeks|Overall survival, Every 36 weeks|Safety and tolerability assessed by abnormal lab values (hematology, biochemistry, urinalysis), by physical examination and vital signs, Every 36 weeks
This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors